专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 外观设计

USD568562S1 Vacuum cleaner 有权
公开(公告)号：USD568562S1
公开(公告)日：2008-05-06
申请号：US29279946
申请日：2007-05-11
申请人： John Griffin , Robert L. Crevling, Jr. , Liu H. Li
设计人： John Griffin , Robert L. Crevling, Jr. , Liu H. Li

52. 发明申请

US20080091311A1 APPARATUSES AND METHODS FOR DISPLAYING AND RECEIVING TACTICAL AND STRATEGIC FLIGHT GUIDANCE INFORMATION 有权
标题翻译：显示和接收战术和战略指导信息的装置和方法
公开(公告)号：US20080091311A1
公开(公告)日：2008-04-17
申请号：US11639791
申请日：2006-12-14
申请人： Daniel Boorman , John Griffin , Peter Gunn , Randall Mumaw
发明人： Daniel Boorman , John Griffin , Peter Gunn , Randall Mumaw
IPC分类号： G01C23/00 , G06F17/00
CPC分类号： G08G5/0021 , G01C23/00 , G08G5/0052
摘要： Methods and apparatuses for displaying and receiving tactical and strategic flight guidance information are disclosed. A method in accordance with one aspect of the invention includes displaying at least one first indicator to an operator of the aircraft, with a first indicator corresponding to a first instruction input by the operator for directing a first aircraft behavior and implemented upon receiving an activation instruction from the operator. At least one second indicator corresponding to a second instruction for directing a second aircraft behavior at least proximately the same as the first aircraft behavior is displayed, with the at least one second instruction to be automatically implemented at a future time. The at least one second indicator is at least approximately the same as the at least one first indicator. Indicators can be hierarchically organized to simplify presentation and reduce pilot training time.
摘要翻译：公开了显示和接收战术和战略飞行指导信息的方法和装置。根据本发明的一个方面的方法包括将至少一个第一指示符显示给飞行器的操作者，其中第一指示符对应于由操作者输入的用于指示第一飞行器行为并在接收到激活指令时实现的第一指令从运营商。显示对应于用于将第二飞行器行为至少接近地与第一飞行器行为相同的第二指令的至少一个第二指示符，其中至少一个第二指令将在将来的时间自动实现。至少一个第二指示器至少与至少一个第一指示器大致相同。指标可以分层组织，以简化演示，减少飞行员培训时间。

53. 发明申请

US20070276128A1 Stabilized Proteins with Engineered Disulfide Bonds 失效
标题翻译：具有工程二硫键的稳定蛋白质
公开(公告)号：US20070276128A1
公开(公告)日：2007-11-29
申请号：US11627197
申请日：2007-01-25
申请人： John Griffin , Andrew Gale , Elizabeth Getzoff , Jean-Luc Pellequer
发明人： John Griffin , Andrew Gale , Elizabeth Getzoff , Jean-Luc Pellequer
IPC分类号： C07K14/755 , C07K1/00
CPC分类号： C07K1/1075 , A61K38/00 , C07K1/107 , C07K14/745 , C07K14/755
摘要： The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.
摘要翻译：本发明涉及将一种或多种半胱氨酸残基引入多肽的方法，所述多肽允许通过在多肽的不同结构域之间形成至少一个键，优选二硫键来稳定多肽。本发明还涉及含有这种引入的半胱氨酸残基的多肽，编码这些多肽的核酸和包含这种多肽或核酸的药物组合物。本发明还涉及含有这种核酸的载体，病毒颗粒和宿主细胞，以及使用它们产生本发明多肽的方法。示例性多肽包括血浆蛋白，包括肝细胞生长因子激活剂和血浆透明质酸结合蛋白，以及凝血因子，如因子VIII，因子V，因子XII和凝血酶原。

54. 发明授权

US07199126B2 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase 失效
标题翻译：用于抑制激酶和/或HMG-CoA还原酶的组合物和治疗
公开(公告)号：US07199126B2
公开(公告)日：2007-04-03
申请号：US11118065
申请日：2005-04-29
申请人： John Griffin , Guido Lanza , Jessen Yu
发明人： John Griffin , Guido Lanza , Jessen Yu
IPC分类号： A01N43/54
CPC分类号： A61K31/4439 , A61K31/4172 , A61K31/4178 , A61K31/506 , C07D401/04 , C07D403/04 , C07D405/14 , Y02A50/409
摘要： The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
摘要翻译：本发明提供了用于治疗MAP激酶相关病症和/或HMG-CoA还原酶相关病症的物质，试剂盒和方法的组合物。特别地，本发明提供了通过抑制p38alpha MAP激酶和/或HMG-CoA还原酶来治疗动物受试者的炎性和/或心血管疾病的组合物，以及提供施用这种组合物的制剂和模式。本发明还提供了用于实施本发明的MAP激酶，HMG-CoA还原酶抑制剂或两者的合理设计的方法。

55. 外观设计

USD538863S1 Exercise machine 有权
公开(公告)号：USD538863S1
公开(公告)日：2007-03-20
申请号：US29224007
申请日：2005-02-22
申请人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi
设计人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi

56. 发明申请

US20060263796A1 Dyslipoproteinemia associated with venous thrombosis 审中-公开
标题翻译：与静脉血栓相关的血脂异常
公开(公告)号：US20060263796A1
公开(公告)日：2006-11-23
申请号：US11347632
申请日：2006-02-03
申请人： John Griffin , Hiroshi Deguchi , Darlene Elias , Natalie Pecheniuk
发明人： John Griffin , Hiroshi Deguchi , Darlene Elias , Natalie Pecheniuk
IPC分类号： C12Q1/68 , G01N33/92
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N33/92 , G01N2800/226 , Y10T436/143333
摘要： The present invention provides methods of determining a human subject's risk for venous thrombosis based on the finding that venous thrombosis patients have significantly lower levels of large HDL particles, HDL-cholesterol and apolipoprotein Al and higher levels of small LDL particles, LDL-cholesterol and apolipoprotein B. Genotyping showed that venous thrombosis patients differed significantly from controls in CETP genotype and that the CETP genotypes found in subjects with VTE are linked to elevated CETP mass and activity. Methods for determining the level of lipids or lipoproteins in plasma or serum samples to determine risk for venous thrombosis are provided. Methods for reducing the risk of venous thrombosis are also provided.
摘要翻译：本发明提供了基于静脉血栓形成患者具有显着较低水平的大HDL颗粒，HDL-胆固醇和载脂蛋白A1以及更高水平的小LDL颗粒，LDL-胆固醇和载脂蛋白的发现来确定人受试者的静脉血栓形成风险的方法 B.基因分型表明，静脉血栓形成患者与CETP基因型的对照差异显着，VTE患者发现的CETP基因型与升高的CETP质量和活性有关。提供了确定血浆或血清样品中脂质或脂蛋白水平以确定静脉血栓形成风险的方法。还提供降低静脉血栓形成风险的方法。

57. 外观设计

USD531239S1 Exercise machine 有权
公开(公告)号：USD531239S1
公开(公告)日：2006-10-31
申请号：US29224008
申请日：2005-02-22
申请人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi
设计人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi

58. 外观设计

USD531238S1 Exercise machine 有权
公开(公告)号：USD531238S1
公开(公告)日：2006-10-31
申请号：US29224006
申请日：2005-02-22
申请人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi
设计人： Lynn D. Hoggan , John Griffin , James R. Richards , Michael K. Durtschi

59. 发明申请

US20050288306A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase 失效
公开(公告)号：US20050288306A1
公开(公告)日：2005-12-29
申请号：US11118064
申请日：2005-04-29
申请人： John Griffin , Guido Lanza , Jessen Yu
发明人： John Griffin , Guido Lanza , Jessen Yu
IPC分类号： A61K31/4178 , A61K31/4439 , A61K31/506
CPC分类号： A61K31/4178 , A61K31/4439 , A61K31/506
摘要： The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

60. 发明申请

US20050282883A1 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase 审中-公开
标题翻译：用于抑制激酶和/或HMG-CoA还原酶的组合物和治疗
公开(公告)号：US20050282883A1
公开(公告)日：2005-12-22
申请号：US11118113
申请日：2005-04-29
申请人： John Griffin , Guido Lanza , Jessen Yu
发明人： John Griffin , Guido Lanza , Jessen Yu
IPC分类号： A61K31/401 , A61K31/4025 , A61K31/405
CPC分类号： A61K31/401 , A61K31/4025 , A61K31/405 , A61K2300/00
摘要： The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA-reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
摘要翻译：本发明提供了用于治疗MAP激酶相关病症和/或HMG-CoA还原酶相关病症的物质，试剂盒和方法的组合物。特别地，本发明提供了通过抑制p38alpha MAP激酶和/或HMG-CoA还原酶来治疗动物受试者的炎性和/或心血管病症的组合物，以及提供给予这种组合物的制剂和模式。本发明还提供了用于实施本发明的MAP激酶，HMG-CoA还原酶抑制剂或两者的合理设计的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式